**ERRATA - ICD-10 MS-DRGs Version 39.1 Effective April 1, 2022**

In response to the COVID-19 pandemic, the Centers for Medicare & Medicaid Services (CMS) is implementing 2 new procedure codes, in addition to the 7 new procedure codes previously announced, bringing the total to 9 new procedure codes to describe the introduction or infusion of therapeutics, including vaccines for COVID-19 treatment, into the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective April 1, 2022.

CMS notes that for hospitalized patients, Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such, Medicare expects that the appropriate [CPT codes](https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies) will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient. For details on billing Medicare for the COVID-19 vaccine appropriately, please see this page in our provider toolkit: <https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>.

The ICD-10 MS-DRG Grouper assigns each case into an MS-DRG based on the reported diagnosis and procedure codes and demographic information (age, sex, and discharge status).

The ICD-10 Medicare Code Editor (MCE) Version 39.1 software uses edits to detect and report errors in the claims data for the ICD-10 codes reported to validate correct coding on claims for discharges on or after April 01, 2022.

The ICD-10 MS-DRG Grouper software package to accommodate these 2 new additional codes, Version 39.1, is effective for discharges on or after April 01, 2022. As indicated in the table below, these codes will not affect the MS-DRG assignment.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Procedure Code** | **Description** | **\*O.R.** | **MDC** | **MS-DRG** |
| XW023X7 | Introduction of tixagevimab and cilgavimab monoclonal antibody into muscle, percutaneous approach, new technology group 7 | N |  |  |
| XW023Y7 | Introduction of other new technology monoclonal antibody into muscle, percutaneous approach, new technology group 7 | N |  |  |

\*As the procedure codes are designated as non-O.R. procedures, there is no assigned MDC or MS-DRG. The ICD-10 MS-DRG assignment is dependent on the reported principal diagnosis, any secondary diagnoses defined as a complication or comorbidity (CC) or major complication or comorbidity (MCC), procedures or services performed, age, sex, and discharge status.

The ICD-10 MS-DRG V39.1 Grouper Software, Definitions Manual Table of Contents and the Definitions of Medicare Code Edits V39.1 manual will be available at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html>

# FY 2022 Update Summary

# Change Summary Table

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **2021 Total** | **New Codes** | **Revised Titles** | **Deleted Codes** | **2022 Total** |
| 78,136 | 200 | 62 | 107 | **78,229** |

**ICD-10-PCS Code FY 2022 Totals, By Section**

|  |  |
| --- | --- |
| Medical and Surgical | 67,754 |
| Obstetrics | 304 |
| Placement | 861 |
| Administration | 1,253 |
| Measurement and Monitoring | 422 |
| Extracorporeal or Systemic Assistance and Performance | 52 |
| Extracorporeal or Systemic Therapies | 46 |
| Osteopathic | 100 |
| Other Procedures | 78 |
| Chiropractic | 90 |
| Imaging | 2,977 |
| Nuclear Medicine | 463 |
| Radiation Therapy | 2,087 |
| Physical Rehabilitation and Diagnostic Audiology | 1,380 |
| Mental Health | 30 |
| Substance Abuse Treatment | 59 |
| New Technology | 273 |
| **Total** | **78,229** |

**TABLE ADDENDA**

|  |  |
| --- | --- |
| *Section* | **X** New Technology |
| *Body System* | **W** Anatomical Regions |
| *Operation* | **0** Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |

|  |  |  |  |
| --- | --- | --- | --- |
| *Body Part* | *Approach* | *Device / Substance / Technology* | *Qualifier* |
| **2** Muscle | **3** Percutaneous | **V** COVID-19 Vaccine Dose 3 **W** COVID-19 Vaccine Booster **ADD X** Tixagevimab and Cilgavimab Monoclonal Antibody **ADD Y** Other Monoclonal Antibody | **7** New Technology Group 7 |